Problems in the Evaluation of Theoretical Risks for Humans to Become Infected with BSE-Contaminated Bovine-Derived Pharmaceutical Products

  • Maurizio Pocchiari
Part of the Serono Symposia USA Norwell, Massachusetts book series (SERONOSYMP)


The safety of bovine-derived pharmaceutical products with respect to bovine spongiform encephalopathy (BSE) has been the topic of several scientific meetings in the last few years (1–13), and although a consensus on the factors that must be considered for their evaluations has been reached, it is still difficult for manufacturers and authorities to defermine an objective estimate of the potential level of BSE contamination for each drug or to allocate precise figures to each risk factor. This chapter weighs each risk factor in order to facilitate uniform application by competent authorities. However, this chapter does not give a magic formula with which to decide whether a product should be kept on, or removed from, the market. The decision regarding the usefulness of a medicinal product should take into consideration not only the estimated potential risk but also, and most important, its inherent benefit.


Medicinal Product European Economic Community Transmissible Spongiform Encephalopathy Residual Infectivity Restrictive Figure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bovine Spongiform Encephalopathies (BSE) Roundtable. Bethesda, MD: National Institutes of Health, 1989.Google Scholar
  2. 2.
    BSE and related agents: risk factors of biological products. An informal consultation, 1990, Annecy, France.Google Scholar
  3. 3.
    International meeting. Virological aspects of the safety of biological products, 1990, London. In: International Association of Biological Standardization, ed. Developments in biological standards, vol 75. Basel: Karger, 1991.Google Scholar
  4. 4.
    BSE Seminar, 1990, Brussels (Belgium). In: Bradley R, Savey M, Marchant B, eds. Sub-acute spongiform encephalopathies. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1991.Google Scholar
  5. 5.
    Mad cow disease (BSE)—danger by food and drugs? 1991, Bonn, Germany.Google Scholar
  6. 6.
    Roundtable/workshop on public health issues associated with bovine spongiform encephalopathy. Bethesda, MD: National Institutes of Health, 1991.Google Scholar
  7. 7.
    Transmissible spongiform encephalopathies: their impact on the safety of medicinal products. Lagen, Germany: Paul-Ehrlich-Institut, 1991.Google Scholar
  8. 8.
    Committee for Proprietary Medicinal Products. Ad hoc working party on biotechnology/pharmacy on safety of medicines: EEC regulatory document. Note for guidance. Guidelines for minimizing the risk of transmission of agents causing spongiform encephalopathies via medicinal products, 1991, Brussels, Belgium. Biologicals 1992;20:155–158.CrossRefGoogle Scholar
  9. 9.
    WHO. Consultation on public health issues, related to animal and human spongiform encephalopathies, 1991, Geneva: WHO Bull 1992;70:183–190.Google Scholar
  10. 10.
    International Meeting on Transmissible Spongiform Encephalopathies. Impact on animal and human health, 1992, Heidelberg, Germany. In: International Association of Biological Standardization, ed. Developments in biological standards, vol 80. Basel: Karger, 1993.Google Scholar
  11. 11.
    Bovine spongiform encephalopathy—where are we now? European Commission Meeting of the Scientific Veterinary Committee with Scientific Experts, 1993, Brussels, Belgium. In: Bradley R, Marchant B, eds. Transmissible spongiform encephalopathies. Brussels: Working Document for the European Commission, Ref.: F.II.3-JC/0003, 1994.Google Scholar
  12. 12.
    Symposium, “Transmissible spongiform encephalopathies,” 1993, Berlin.Google Scholar
  13. 13.
    VI International Workshop on Bovine Spongiform Encephalopathy “The BSE Dilemma,” 1995, Williamsburg, VA.Google Scholar
  14. 14.
    Savey M, Coudert M, Jobert JL, Fontaine JJ, Belli P. Bovine spongiform encephalopathy (BSE) risk assessment and surveillance in France. In: Bradley R, Marchant B, eds. Transmissible spongiform encephalopathies. Brussels: Working Document for the European Commission, Ref.: F.II.3-JC/0003, 1994:57–67.Google Scholar
  15. 15.
    Guarda F, Castiglione F, Agrimi U, Cardone F, Caracappa S, Pocchiari M. Bovine spongiform encephalopathy in Italy. Eur J Vet Pathol 1995;1:71–72.Google Scholar
  16. 16.
    Fraser H, Bruce ME, Chree A, McConnell I, Wells GAH. Transmission of bovine spongiform and scrapie to mice. J Gen Virol 1992;73:1891–1897.PubMedCrossRefGoogle Scholar
  17. 17.
    Fraser H, Foster JD. Transmission to mice, sheep and goats and bioassay of bovine tissues. In: Bradley R, Marchant B, eds. Transmissible spongiform encephalopathies. Brussels: Working Document for the European Commission, Ref.: F.II.3-JC/0003, 1994:145–159.Google Scholar
  18. 18.
    Hadlow WJ, Kennedy RC, Race RE, Eklund CM. Virologic and neurohistologic findings in dairy goats affected with natural scrapie. Vet Pathol 1980; 17:187–199.PubMedCrossRefGoogle Scholar
  19. 19.
    Hadlow WJ, Kennedy RC, Race RE. Natural infection of Suffolk sheep with scrapie virus. J Infect Dis 1982;146:657–664.PubMedCrossRefGoogle Scholar
  20. 20.
    Taylor DM, Dickinson AG, Fraser H, Robertson PA, Salcinski PR, Lowry PJ. Preparation of growth hormone free from contamination with unconventional viruses. Lancet 1985;2:260–262.PubMedCrossRefGoogle Scholar
  21. 21.
    Pocchiari M, Macchi G, Peano S, Conz A. Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Arch Virol 1988;98:131–135.PubMedCrossRefGoogle Scholar
  22. 22.
    Diringer H, Braig HR. Infectivity of unconventional viruses in dura mater. Lancet 1989;1:439–440.PubMedCrossRefGoogle Scholar
  23. 23.
    Dormont D, Deslys JP, Bouissin F, et al. Inactivation of unconventional slow viruses and HIV in human extractive biological products used in human therapy. Biotechnol Plasma Proteins 1989;175:355–364.Google Scholar
  24. 24.
    Pocchiari M, Peano S, Conz A, et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res 1991;35:161–166.PubMedCrossRefGoogle Scholar
  25. 25.
    Di Martino A, Safar J, Ceroni M, Gibbs CJ Jr. Purification of non-infectious ganglioside preparations from scrapie-infected brain tissue. Arch Virol 1992;124:111–121.PubMedCrossRefGoogle Scholar
  26. 26.
    Di Martino A, Safar J, Gibbs CJ Jr. The consistent use of organic solvents for purification of phospholipids from brain tissue effectively removes scrapie infectivity. Biologicals 1994;22:221–225.PubMedCrossRefGoogle Scholar
  27. 27.
    Pocchiari M. Methodological aspects of the validation of purification procedures of human/animal derived products to remove unconventional slow viruses. Dev Biol Stand 1991;75:87–95.PubMedGoogle Scholar
  28. 28.
    Fraser H. The pathology of natural and experimental scrapie. In: Kimberlin RH, ed. Slow virus disease of animals and man. Amsterdam: North-Holland, 1976:267–305.Google Scholar
  29. 29.
    Brown P. Iatrogenic Creutzfeldt-Jakob disease. Aust NZ J Med 1990;20:633–635.CrossRefGoogle Scholar
  30. 30.
    Reed LJ, Muench H. A simple method of estimating 50% endpoints. Am J Hyg 1938;27:493–497.Google Scholar
  31. 31.
    Rohwer RG. Virus-like sensitivity of the scrapie agent to heat inactivation. Science 1984;223:600–602.PubMedCrossRefGoogle Scholar
  32. 32.
    Rohwer RG. Scrapie infectious agent is virus-like in size and susceptibility to inactivation. Nature 1984;308:658–662.PubMedCrossRefGoogle Scholar
  33. 33.
    Kimberlin RH, Walker CA. Pathogenesis of experimental scrapie. In: Bock G, Marsh J, eds. Novel infectious agents and the central nervous system. Ciba Foundation Symposium 135. Chichester, UK: John Wiley & Sons, 1988:37–54.Google Scholar
  34. 34.
    Pocchiari M, Salvatore M, Ladogana A, et al. Experimental drug treatment of scrapie: a pathogenetic basis for rationale therapeutics. Eur J Epidemiol 1991;7:556–561.PubMedCrossRefGoogle Scholar
  35. 35.
    Prusiner SB, Cochran SP, Alpers MP. Transmission of scrapie in hamsters. J Infect Dis 1985;152:971–978.PubMedCrossRefGoogle Scholar
  36. 36.
    Kimberlin RH, Walker CA. Pathogenesis of scrapie in mice after intragastric infection. Virus Res 1989;12:213–220.PubMedCrossRefGoogle Scholar
  37. 37.
    Barlow RM, Middleton DJ. Dietary transmission of bovine spongiform encephalopathy to mice. Vet Rec 1990;126:111–112.PubMedGoogle Scholar
  38. 38.
    Taylor DM, Fraser H, McConnell I, et al. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 1994; 139:313–326.PubMedCrossRefGoogle Scholar
  39. 39.
    Brown P, Cathala F, Rauberats RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987;37:895–904.PubMedGoogle Scholar
  40. 40.
    Alperovitch A, Brown P, Weber T, Pocchiari M, Hofman A, Will R. Incidence of Creutzfeldt-Jakob disease in Europe in 1993. Lancet 1994;343:918.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1996

Authors and Affiliations

  • Maurizio Pocchiari

There are no affiliations available

Personalised recommendations